Hematologic diseases
Conditions
Interventions
This is a non-randomized, single-arm, open clinical trial. The show will be for convenience, with 20 participants expected to be recruited, where patients from the hemato-oncology ward of the Hospital
are undergoing treatment for hematological cancer
and have medical clearance to participate in the research. Thus, participants who: have metastasis will be disqualified
exacerbated diseases (e.g. severe cardiovascular or respiratory diseases)
contraindication for the use of electromassage
loss of sensitivity, acute skin injuries and/or devitalized skin
and poor general health that makes it impossible to carry out all assessments. The intervention consists of applying therapeutic massage together with electromassage gloves. The electrical current us
E02.190.599.750.750
E02.190
Sponsors
Hospital de Clínicas da Universidade Federal do Paraná
Universidade Federal do Paraná
Eligibility
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: Individuals of both male and female ages between 18 and 59 years old; diagnosis of hematological cancer; being treated for hematological cancer; and, medical clearance to participate in the research
Exclusion criteria
Exclusion criteria: Patients with the presence of metastasis; exacerbated diseases (e.g. severe cardiovascular or respiratory diseases); contraindication for the use of electromassage: loss of sensitivity, acute skin injuries and/or devitalized skin; and poor general health that makes it impossible to carry out all assessments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate pain in hemato-oncology patients, using the method determined using the Visual Analogue Scale (VAS). Considering the classification of pain as: no pain (0), mild pain (1 to 3), moderate pain (4 to 6), severe pain (7 to 10) and the worst pain imaginable (10) | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find a reduction in fatigue, and an improvement in emotional aspects and quality of sleep and quality of life. Variables measured, respectively, through: the Fatigue Severity Scale (FSS) - The FSS consists of nine items, each scored from 1 (completely disagree) to 7 (completely agree), the total score varies from 9 to 63 points , with higher scores indicating greater severity of the patient's fatigue; of the Hospital Anxiety and Depression Scale (HAD) - It consists of 14 questions, divided into anxiety and depression subscales, each containing seven items. The established cutoff points are 8 for anxiety and 9 for depression. The results are categorized as follows: 0 to 7 points indicate an unlikely probability; 8 to 11 points indicate a questionable or doubtful possibility; and 12 to 21 points indicate a probable probability; of the Pittsburg Sleep Quality Index (PSQI) - The PSQI is a questionnaire composed of 19 items grouped into seven components that can be scored from 0 to 3. These components are: (i) subjective sleep quality; (ii) sleep latency; (iii) sleep duration; (iv) habitual sleep efficiency; (v) sleep changes; (vi) use of sleep medications; and (vii) daytime dysfunction. The score can range from 0 to 21 points, where a score of 0 to 4 points suggests good sleep quality, 5 to 10 points indicates poor sleep quality and scores above 10 suggest the presence of sleep disorders; and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) - The EORTC QLQ-C30 is composed of five functional elements (physical, cognitive, emotional, social functions and role performance), three symptomatic components (fatigue, pain, nausea and vomiting), a quality of life (QoL) scale and assessment of global health. Additionally, specific symptoms are assessed, such as dyspnea, lack of appetite, insomnia, constipation, diarrhea and financial impact caused by the disease and treatment. Responses are indi | — |
Countries
Brazil
Contacts
Public ContactNatália Moreira
Universidade Federal do Paraná
Outcome results
None listed